Gapping up
In reaction to strong earnings/guidance:
- LEN +8.9%, FDS +0.5%
Other news:
- SPPI +21.2% (reports the company is weighing a possible sale after fielding takeover interest)
- XERS +18.1% (announces positive phase 3 clinical trial data on its investigational ready-to-use glucagon rescue pen)
- CBIO +8.5% (Point72 discloses 5.5% passive stake)
- EXEL +5.4% (will replace Copart in the S&P MidCap 400)
- PTIE +5.2% (trading higher but currently halted - FDA is holding an Advisory Committee Meeting to discuss the New Drug Application (NDA) for REMOXY ER today)
- GE +5.1% (announces results of strategic review -- confirms will separate GE Healthcare into a standalone company, will pursue an orderly separation from Baker Hughes (BHGE))
- KMI +0.8% (Kinder Morgan, EagleClaw Midstream and Apache announce joint development of the Permian Highway Pipeline Project)
- APA +0.8% (Kinder Morgan, EagleClaw Midstream and Apache announce joint development of the Permian Highway Pipeline Project)
Analyst comments:
- LRCX +2.3% (upgraded to Buy from Neutral at UBS)
- MU +2.2% (upgraded to Neutral from Sell at UBS)
- HOME +2% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- SPOT +2% (initiated with a Overweight at Barclays)
- CTL +1.9% (upgraded to Buy from Hold at Jefferies)
- WH +1.8% (added to Conviction Buy List at Goldman)
- MELI +1.4% (upgraded to Overweight from Sector Weight at KeyBanc Capital Mkts)
- NVDA +1.1% (initiated with a Buy at The Benchmark Company)